Hep C Tx Shows Promise in Hospitalized COVID-19 Patients

(MedPage Today) — A higher percentage of hospitalized COVID-19 patients treated with sofosbuvir and daclatasvir (SOF/DCV), a two-drug hepatitis C virus (HCV) combination therapy, experienced clinical improvement versus patients receiving control…

Source link

Related posts

An advisor can help take the emotion out of investing


An unusual biliary “pearl”


Transgenerational Self-Reconstruction of Disrupted Chromatin Organization After Exposure To An Environmental Stressor in Mice


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World